Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM)
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.06.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Cindy Varga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC. Electro…. Hauptthemen laut MEDLINE: Blood Proteins, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Proteome. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Wake Forest Clinical and Translational Science Institute.
Abstract (Originalsprache)
BACKGROUND: Compared to Non-Hispanic Whites, African American (AA) individuals have a 2-fold higher incidence of MGUS and MM. Understanding the molecular mechanisms that drive progression from MGUS to MM is crucial, but few studies have explored whether there are differences in protein expression patterns in the progression of MGUS to MM by race. Here, we used mass-spectrometry to compare proteomic profiles between AA and White individuals with MGUS and MM. We hypothesized that biological differences between MGUS and MM could be captured by measuring protein presence and abundance. The primary aim was to identify protein pathways distinguishing these 2 stages. METHODS: In this study, we conducted untargeted serum protein profiling using data-independent acquisition mass spectrometry proteomics, quantifying over 1550 proteins in 30 MGUS and 30 newly diagnosed, treatment-naive MM samples. Samples were evenly split by self-reported race and matched for age and sex. Linear and logistic regression models were used to test for association between protein abundance or presence and MGUS/ MM status, adjusting for sex, age, BMI, batch, and race as covariates. Missing values in logistic regression were imputed as 0, with all other values set to 1. Proteins with unadjusted P < .05 were selected for pathway and network analysis. RESULTS: No significant differences were observed between AA and White patients with MM in M-spike level (P = .644), light chain involvement (P = .122), or plasmacytosis (P = .877). Proteomic analysis identified 26 proteins that significantly differed in detection or in abundance between MGUS and MM samples in a race agnostic manner (P < .05), with 15 showing increased abundance in MM and 11 varying in detection rates (presence or absence). Among these, ICAM-3, HSP90B1, ORM2, MAN1A1, OSCAR, PRKDC, and cDNA-FLJ-41552 (interaction P < .05) were particularly notable. Two proteins, PRKDC and cDNA FLJ41552 were decreased exclusively in AA patients with MM (interaction P < .05), suggesting population specific differences. Notably, 16 proteins showed changes between MGUS and MM exclusively in White patients (interaction P < .05), with the most significant being SERPIND1, C4B, CPN1, CNDP1 in abundance, and SERPINE1, CA2, CD109 in detection. CONCLUSION: While the exact roles of these molecular pathways in the progression from MGUS to MM remain unclear, the identified protein differences may serve as biomarkers and therapeutic targets, warranting further validation and functional studies for clinical application. In addition, the differential expression of PRKDC in AA patients suggests potential population-specific vulnerabilities. Validation of these findings in additional cohorts will help assess the potential usefulness of these biomarkers in predicting transition from MGUS to MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC. Electronic address: cindy.varga@advocatehealth.org.
- Center for Precision Medicine, Wake Forest University School of Medicine, Winston Salem, NC.
- Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC.
Förderung
- Wake Forest Clinical and Translational Science Institute
Zitieren
APA
Varga, C., Zimmerman, K. D., Foureau, D. M., Nazli, S. A., Voorhees, P. M., Atrash, S., Paul, B., Ferreri, C., Olivier, M., & Bhutani, M. (2025). Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM). Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.06.008
Vancouver
Varga C, Zimmerman KD, Foureau DM, Nazli SA, Voorhees PM, Atrash S, et al. Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM). Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.06.008
BibTeX
@article{Varga2025,
author = {Varga, Cindy and Zimmerman, Kip D and Foureau, David M and Nazli, Sumaiya A and Voorhees, Peter M and Atrash, Shebli and Paul, Barry and Ferreri, Christopher and Olivier, Michael and Bhutani, Manisha},
title = {Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM)},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.06.008}
}
EUVIMED